PBAC's latest decision on Ocriplasmin: Recommended with restriction (2019). Considered for Vitreomacular traction syndrome (VTS), including when associated with macular hole of diameter ≤400 microns.
PBAC outcome
Recommended with restriction
Authority Required
ICER (AUD/QALY)
Not modelled
no economic evaluation
Submissions
3
first 2014
Submissions
3
2014 → 2019
Eligible population
Adults with visual impairment due to vitreomacular traction (VMT) without or with full thickness macular hole ≤400 micrometres, best corrected visual acuity ≥20/25 or worse, vitreomacular adhesion diameter ≤1500 micrometres, no epiretinal membrane, previously untreated, no prior vitrectomy, and symptomatic.
Therapy area
Ophthalmology
Line of therapy
First-line
Evidence base
Cost-minimisation
Economic model
Cost-minimisation
ICER note
No economic analysis conducted; minor submission for formulation change only.
ICER (historical)
$15k/QALY–$45k/QALY in an earlier submission (2016) — the latest submission carried no numeric base case. No single PSD states this combined range; see source PSDs.
Risk sharing
Risk-sharing arrangement in place — Special Pricing Arrangement (SPA) applies; existing Deed of Agreement between the Commonwealth and Novartis.
Submission history
Nov 2014: Not recommended · Authority Required
Mar 2016: Recommended with restriction · Authority Required — ICER $45k/QALY
Mar 2019: Recommended with restriction · Authority Required